GLU2 Antibody

What is GLUT2 and why is it important in metabolic research?

GLUT2 (also known as SLC2A2) belongs to the facilitative glucose transporter protein family, which comprises 13 members. It is an integral membrane protein with 12 transmembrane domains that mediates the transport of glucose, fructose, and galactose across cell membranes. GLUT2's significance stems from its low-affinity (Km ~17 mM) and high-capacity glucose transport capabilities, making it most efficient at relatively high glucose concentrations .

GLUT2 is primarily expressed in:

• Hepatocytes (liver cells)

• Pancreatic beta cells

• Intestinal epithelial cells

• Kidney epithelium

• Recently discovered in T cells

Its importance in research lies in its role as a glucose sensor in pancreatic beta cells and its bidirectional glucose transport function, which is critical for maintaining glucose homeostasis. Dysregulation of GLUT2 has been implicated in metabolic disorders like diabetes .

What are the key differences between various GLUT2 antibodies available for research?

Different GLUT2 antibodies target distinct epitopes, affecting their performance in various applications:

The choice of antibody should be based on the specific application and research question. For detection of GLUT2 in intact tissues, antibodies targeting the extracellular domains often perform better than those targeting intracellular domains .

How can I verify the specificity of my GLUT2 antibody?

Verifying specificity is crucial for reliable results. Implement these validation methods:

• Peptide competition assays: Pre-incubate antibody with excess antigenic peptide before application. Specific staining should be abolished or significantly reduced, as demonstrated in studies using both C-terminal and extracellular loop antibodies .

• Knockout/knockdown controls: Use tissues or cells from GLUT2 knockout animals or GLUT2-silenced cells. The staining should be absent or significantly reduced in these samples .

• Multiple antibodies approach: Use antibodies targeting different epitopes of GLUT2. Similar staining patterns with different antibodies increase confidence in specificity .

• Western blot molecular weight verification: GLUT2 should appear at approximately 57 kDa (calculated), though observed molecular weights can range between 60-70 kDa or 38-45 kDa due to post-translational modifications, particularly N-glycosylation .

• Positive control tissues: Include known GLUT2-expressing tissues such as liver, pancreas, and kidney samples in your experiments .

How does epitope accessibility affect GLUT2 detection in different cellular compartments?

Epitope accessibility presents a significant challenge in GLUT2 detection, particularly in different cellular compartments. Research has revealed:

• Membrane topology effects: GLUT2 has 12 transmembrane domains with intracellular N- and C-termini. In intact cells or tissues, antibodies targeting the C-terminal region (residues 508-522) often fail to detect GLUT2 at the brush-border membrane, despite successfully detecting it in Western blots of the same samples .

• Protein-protein interactions: The C-terminal of GLUT2 may be masked by docking proteins in certain cellular locations, particularly at the brush-border membrane. This masking prevents antibody binding despite GLUT2 being present .

• Subcellular localization dynamics: GLUT2 traffics between different cellular compartments in response to stimuli like PMA (phorbol 12-myristate 13-acetate) treatment or changes in glucose levels. This dynamic localization can affect epitope exposure .

• Solution for detection in intact tissues: Antibodies targeting the extracellular loop between transmembrane regions 1 and 2 (residues 40-55) have been shown to successfully detect GLUT2 at both basolateral and brush-border membranes in immunohistochemistry .

These findings emphasize the importance of selecting antibodies with appropriate epitope targets based on the specific cellular compartment being studied.

What are the challenges in detecting glycosylated GLUT2 and how can they be overcome?

Glycosylation of GLUT2 presents several challenges for antibody detection:

• Interference with antibody binding: The presence of complex sugar chains linked to the N-glycosylation site at residue N62 significantly interferes with antibody binding to nearby epitopes, particularly for antibodies targeting the extracellular loop (residues 40-55) .

• Altered molecular weight: Glycosylation increases the observed molecular weight of GLUT2 from the calculated 57 kDa to approximately 60-70 kDa in Western blots, which must be considered when interpreting results .

Effective strategies to overcome these challenges include:

• Enzymatic deglycosylation: Treatment with N-endoglycosidase F has been shown to significantly improve detection of brush-border membrane GLUT2 by removing interfering glycosylation sugars . This approach revealed GLUT2 at the brush-border membrane that was previously undetectable.

• Optimized fixation protocols: When using periodate-lysine-paraformaldehyde (PLP) fixative, be aware that the presence of free sugars in the perfusate can protect glycosylation sugars from oxidation. This can be addressed by modifying fixation protocols or subsequent enzymatic treatment .

• Epitope selection: For applications involving detection of native glycosylated GLUT2, choose antibodies targeting epitopes distant from known glycosylation sites .

• Sample preparation considerations: For Western blotting, denaturing conditions help expose masked epitopes, making detection of glycosylated GLUT2 more reliable compared to immunohistochemistry of intact tissues .

How does GLUT2 expression differ between tissues and how should antibody applications be optimized accordingly?

GLUT2 expression patterns vary significantly across tissues, requiring tailored approaches for optimal detection:

Tissue-specific considerations:

• Intestinal samples: GLUT2 rapidly traffics between membrane compartments in response to glucose levels or PMA. For accurate localization studies, perfuse and fix tissues in situ rather than excising before fixation. This prevents redistribution of GLUT2 during sample preparation .

• T cells: GLUT2 expression in CD8+ T cells is highly regulated by environmental factors including glucose concentration, oxygen availability, and extracellular acidification. For accurate assessment, carefully control these parameters during sample preparation and analysis .

• Pancreatic samples: GLUT2 in pancreatic β-cells is involved in glucose sensing and insulin secretion. Detection is more challenging in diabetic models where GLUT2 expression may be altered. Optimize antibody concentration and consider dual staining with insulin to identify β-cells accurately .

What are the optimal protocols for detecting GLUT2 in different applications?

Western Blotting (WB):

• Protein loading: 15-20 μg protein per lane is generally sufficient

• Recommended dilutions: 1:500-1:3000 for polyclonal antibodies; 1:1000-1:10000 for monoclonal antibodies

• Molecular weight considerations: Look for bands at 57 kDa (calculated), though 60-70 kDa and 38-45 kDa bands are commonly observed due to glycosylation

• Detection method: ECL (Enhanced ChemiLuminescence) provides good sensitivity

• Controls: Include positive control samples from liver, pancreas, or kidney tissue

Immunohistochemistry (IHC):

• Fixation: Periodate-lysine-paraformaldehyde (PLP) fixative is effective, but be aware that free sugars in the perfusate can protect glycosylation sugars

• Antibody selection: Extracellular loop antibodies (residues 40-55) are recommended for detection of membrane-localized GLUT2

• Enzymatic treatment: Consider N-endoglycosidase F treatment to remove interfering glycosylation sugars for improved detection

• Dilutions: 1:50-1:1000 depending on the antibody and tissue type

• Visualization: HRP-DAB staining with hematoxylin counterstain works well for paraffin-embedded sections

Flow Cytometry:

• Cell preparation: Single-cell suspensions with minimal processing time

• Antibody selection: Alexa Fluor 488-conjugated antibodies provide good signal-to-noise ratio

• Controls: Include isotype control antibody (e.g., Catalog # IC003G)

• Analysis: Compare filled histogram (GLUT2-stained) with open histogram (isotype control)

How can I optimize GLUT2 detection in tissues with variable expression levels?

Detecting GLUT2 across tissues with varying expression levels requires strategic optimization:

• Antibody titration: Determine optimal antibody concentration for each tissue type. For tissues with lower GLUT2 expression, higher antibody concentrations or longer incubation times may be necessary .

• Signal amplification strategies:

  • For IHC: Consider tyramide signal amplification (TSA) for tissues with low GLUT2 expression

  • For WB: Longer exposure times for ECL detection, but stay within linear range of detection

  • For Flow cytometry: Use brighter fluorophores like PE or Alexa Fluor 488

• Reduce background interference:

  • Block with BSA (1%) and normal serum (10%) from the species of secondary antibody

  • Include 0.3M glycine in blocking buffer to reduce background in formaldehyde-fixed samples

  • For WB, optimize washing steps (3-5 washes of 5-10 minutes each)

• Enhance epitope accessibility:

  • For IHC-P: Optimal antigen retrieval methods (citrate buffer, pH 6.0, or EDTA buffer, pH 9.0)

  • For glycosylated GLUT2: Enzymatic deglycosylation with N-endoglycosidase F

• Quantification approaches:

  • For WB: Establish standard curves with actin or other housekeeping proteins

  • Ensure signal falls within linear range (correlation coefficient >0.99) for accurate quantification

  • For IHC: Use digital image analysis with appropriate controls

What controls should be included in GLUT2 antibody experiments to ensure reliable results?

Robust controls are essential for reliable GLUT2 antibody-based research:

Positive Controls:

• Tissue/cell controls: Include known GLUT2-expressing samples

  • Liver tissue (human, mouse, rat)

  • HepG2 cells (human hepatocellular carcinoma)

  • Pancreatic tissue (especially β-cells)

  • Caco-2 cells (intestinal epithelial model)

• Recombinant protein: Where available, purified GLUT2 protein as positive control for WB

Negative Controls:

• Antibody controls:

  • Primary antibody omission: Tissue stained only with secondary antibody and detection reagents

  • Isotype controls: Especially important for flow cytometry (e.g., Catalog # IC003G for mouse monoclonal antibodies)

• Antigen competition: Pre-incubation of antibody with excess antigenic peptide should abolish specific staining

• Biological controls:

  • GLUT2 knockout/knockdown samples when available

  • Tissues known not to express GLUT2 (e.g., muscle tissue)

Procedural Controls:

• Glycosylation assessment: Compare results before and after N-endoglycosidase F treatment to evaluate impact of glycosylation on detection

• Quantification controls:

  • For WB: Include actin standards (2-40 μg range) to establish linear detection range

  • Background correction using blank film areas adjacent to bands of interest

• Multiple antibody validation:

  • Use antibodies targeting different epitopes (e.g., C-terminal and extracellular loop)

  • Compare results to confirm specificity and evaluate potential epitope masking

Why might my GLUT2 antibody detect protein in Western blot but fail in immunohistochemistry?

This common problem has several potential causes, supported by research findings:

• Epitope masking in intact tissues: The C-terminal of GLUT2 may be masked by docking proteins in certain cellular locations. Research has shown that C-terminal antibodies (residues 508-522) can detect GLUT2 in Western blots but fail to detect it at the brush-border membrane in intact tissues despite its presence .

• Fixation-induced epitope alterations: Some fixatives can modify protein structure or cross-link proteins in ways that mask epitopes. While proteins are denatured in WB, they maintain more of their native structure in fixed tissues .

• Glycosylation interference: N-linked glycosylation at residue N62 can interfere with antibody binding to nearby epitopes. Denaturing conditions in WB disrupt this interference, while it remains problematic in IHC. Treatment with N-endoglycosidase F can significantly improve detection in IHC .

• Dynamic protein trafficking: GLUT2 rapidly relocates between membrane compartments in response to stimuli. Western blotting detects total protein regardless of localization, while IHC depends on protein being present in detectable compartments at the moment of fixation .

Solutions:

• Try antibodies targeting different epitopes, particularly extracellular domains (residues 40-55)

• Consider enzymatic deglycosylation of tissue sections before antibody application

• Optimize antigen retrieval methods for IHC to better expose epitopes

• Ensure fixation occurs in situ to preserve physiological localization

How can I distinguish between specific and non-specific binding of GLUT2 antibodies?

Distinguishing specific from non-specific binding requires systematic validation:

• Peptide competition assays: Pre-incubation of antibody with excess antigenic peptide should abolish specific staining while non-specific binding persists. Studies have demonstrated this with both C-terminal and extracellular loop antibodies .

• Multiple antibody approach: Using antibodies targeting different epitopes of GLUT2 should yield similar staining patterns for specific binding. Research has shown that while C-terminal and extracellular loop antibodies may differ in their ability to detect GLUT2 in certain compartments due to epitope accessibility issues, they should converge after appropriate treatments (e.g., deglycosylation) .

• Molecular weight verification in WB: Specific GLUT2 binding should appear at the expected molecular weight range (57-70 kDa). Multiple bands may indicate degradation products or alternatively spliced variants, but completely different molecular weights should be scrutinized .

• Cellular localization assessment: GLUT2 is a membrane protein, so staining should primarily localize to cell membranes. Diffuse cytoplasmic or nuclear staining likely represents non-specific binding .

• Gradient of antibody concentrations: Specific binding typically shows a dose-dependent relationship with antibody concentration, while non-specific binding may appear more suddenly at higher concentrations.

What factors affect GLUT2 expression and trafficking that might impact antibody detection results?

Understanding factors affecting GLUT2 expression and trafficking is crucial for interpreting antibody detection results:

• Glucose concentration effects:

  • High glucose levels increase GLUT2 expression in hepatocytes

  • In T cells, GLUT2 expression is reduced in response to low glucose conditions, potentially as a mechanism to prevent passive loss of intracellular glucose

  • Consider standardizing glucose levels in experimental media

• Oxygen availability:

  • Hypoxic conditions (5% oxygen) significantly reduce GLUT2 expression in CD8+ T cells compared to normoxia (20% oxygen)

  • GLUT1 and GLUT2 respond differently to oxygen levels, with GLUT1 being upregulated in hypoxia

  • Control oxygen levels when comparing GLUT2 expression across experiments

• Extracellular acidification:

  • Changes in extracellular pH affect GLUT2 expression and localization

  • This is particularly important in inflammatory microenvironments

• Hormonal regulation:

  • Thyroid function affects GLUT2 expression in pancreatic islets

  • Elevated glucocorticoids increase GLUT2 degradation

  • Consider the hormonal status of experimental animals or cell culture conditions

• Pharmacological agents:

  • PMA (phorbol 12-myristate 13-acetate) induces trafficking of GLUT2 to the brush-border membrane

  • PKC βII activation correlates with increased GLUT2 at the brush-border membrane

  • Be aware of potential effects of treatment compounds on GLUT2 trafficking

• Post-translational modifications:

  • N-glycosylation affects antibody detection, particularly for antibodies targeting the extracellular loop

  • Enzymatic deglycosylation with N-endoglycosidase F can unmask epitopes for improved detection

Understanding these factors allows researchers to standardize experimental conditions, properly interpret results, and design appropriate controls for GLUT2 antibody-based research.